SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
KPRX reported Third Quarter 2026 results. The price and volatility reaction is pending.
KPRXearnings

Earnings reactions, page 3

Kiora Pharmaceuticals, Inc. (KPRX) Q3 FY2026 earnings

November 12, 2026 · SharpeIQ Research Desk

Reported results

  • GAAP collaboration revenue was $1.0 million for the third quarter of 2026.
  • GAAP research and development expenses were approximately $1.9 million for the third quarter of 2026.
  • GAAP general and administrative expenses were approximately $1.6 million for the third quarter of 2026.
  • GAAP net loss for the third quarter of 2026 was approximately $1.7 million, or $0.28 per basic and diluted share.
  • The company ended the third quarter with approximately $16.3 million in cash and short-term investments.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →